THE DEVELOPMENT OF ATHEROSCLEROTIC lesions resembles an inflammatory process, and bacterial or viral infection has been implicated in the development of atherosclerosis (14) . Mediators of the inflammatory process found in atherosclerotic lesions include tumor necrosis factor-␣ (TNF-␣), interleukin (IL)-6, and activated nuclear factor-B (NF-B) (5, 17, 25) . TNF-␣ and IL-6 are produced by proliferating arterial smooth muscle cells of atherosclerotic plaques but not by smooth muscle cells of normal vessels (2, 21, 25) . Activation of the genes for TNF-␣ and IL-6 by lipopolysaccharide (LPS) in vascular smooth muscle has been shown (19, 27, 15) suggesting that secretion of inflammatory cytokines by smooth muscle cells in response to infection contributes to the development of atherosclerosis.
The regulatory regions of the IL-6 and TNF-␣ genes are responsive to NF-B (4). NF-B is a family of Rel-related transcription factors that mediate inflammatory processes. In the cytosol, NF-B proteins form heteromeric complexes with members of a family of inhibitory proteins termed IB. NF-B is activated after transduction of a proinflammatory signal that results in the phospyhorylation of IB. The phosphorylated IB is degraded, liberating NF-kB dimers that translocate to the nucleus and initiate transcription of target genes (3) . The predominant NF-B species found in vascular smooth muscle cells are p50 and p65. In normal human arterial blood vessels, staining for p50 and p65 reveals that NF-B is located in the cytoplasm. In atherosclerotic vessels, NF-B is found in the nucleus, consistent with an inflammatory process; in nonatherosclerotic vascular smooth muscle, NF-B is detected in the cytoplasm (5) .
Because of similarities in the development of atherosclerosis and inflammatory processes, there is considerable interest in the potential of anti-inflammatory agents to prevent or retard the development of atherosclerotic lesions. Because salicylates, including acetylsalicylic acid (aspirin), prevent the activation of NF-B in some cell types (13, 20) , we were interested in whether aspirin would inhibit the activation of NF-Bdependent inflammatory cytokines in vascular smooth cells.
Aspirin and salicylate inhibit the activation of NF-B by blocking the phosphorylation event and hence preventing the degradation of IB. The mechanism(s) by which aspirin blocks the phosphorylation of IB is (are) not known. IB is phosphorylated by a 700 kDa complex, IB kinase (IK) (8) , which contains two kinases, IK-1 and IK-2, capable of phosphorylating IB (29) . The two IB kinases have been shown to be differentially regulated by upstream kinases activated through different signal transduction pathways (18) , consistent with the existence of multiple signal transduction pathways culminating in the activation of NF-B. Salicylate and salicylate derivatives have been shown to interfere with signal transduction to specific mitogen-activated protein kinases (MAPK) in response to cytokines (24) . Thus there is the potential that the antiinflammatory effects of aspirin may be cell-type specific or signal transduction-pathway specific.
The original goal of this study was to characterize the initial steps leading to the production of TNF-␣ by vascular smooth muscle cells in vitro in response to stimulation by LPS. Our findings indicated that both NF-B activation, an increase in TNF-␣ mRNA, and secretion of TNF-␣ protein follow LPS stimulation. To determine whether the activation of NF-B was necessary for activation of the TNF-␣ gene, we measured NF-B activation, TNF-␣ mRNA, and TNF-␣ protein synthesis in rat smooth muscle cells in culture after LPS stimulation in the presence and absence of aspirin. Contrary to expectation, aspirin had no effect on NF-B activation and TNF-␣ protein synthesis. In the presence of aspirin, the amount of TNF-␣ mRNA was ϳ50% of that found in the absence of aspirin 30 min after LPS stimulation; after 180 min, there was no aspirin effect in the amount of RNA detected. We found a similar decrease of IL-6 mRNA at 30 min but no effect at 180 min after LPS stimulation in the presence of aspirin.
MATERIALS AND METHODS
Cell culture. Protocols for animal use were approved by Mercer University's Institutional Animal Care and Use Committee. Thoracic aortas were obtained from pentobarbitalanesthetized male 250-g Sprague-Dawley rats. Under sterile conditions, the aortas were opened and the endothelial cells were removed by rubbing the luminal surface. The aortas were incubated overnight in Dulbecco's modified Eagle's medium (DMEM) plus antibiotics (100 IU/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml fungizone). Explants (2 ϫ 2 mm) were then cut, placed in a 10-cm petri dish, and covered with DMEM containing 20% fetal bovine serum (FBS) and antibiotics. The explants were cultured at 37°C in a 5% CO2 incubator. After ϳ1 wk, the cells that had exited were released with trypsin and passed into 24-well plates and grown to confluence in DMEM containing 5% FBS and antibiotics (complete medium). Each batch of isolated cells was immunostained for smooth muscle ␣-actin with a commercial kit (Sigma). Cell protein was measured by the Bradford method (6) . Results reported here were from cells in passages 1-6. Cell viability assay. To determine whether the concentrations of LPS used in the experiments affected cell viability, vascular smooth muscle cells at confluence in 96-well plates were treated with LPS (20 g/ml) for 6 h. Cell viability was assessed by the mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrozolium bromide (MTT) to formazan. At the end of each experiment, cells were incubated with 100 l MTT (0.5 mg/ml) dissolved in phenol red-free DMEM plus 0.5% FBS for 4 h. Formazan was extracted with dimethyl sulfoxide and quantitated in a microplate reader at 595 nm. Cell viability in the presence of 20 g/ml LPS was indistinguishable from viability in the absence of LPS in three individual experiments consisting of five viability determinations.
Cytotoxicity assay for TNF-␣. Biologically active TNF-␣ in the culture medium was measured by an in vitro cytotoxicity assay using the murine fibroblast L929 cells as described previously (10) . L929 cells were seeded into 96-well microtiter plates at an initial density of 5.0 ϫ 10 4 cells/well in 200 l of DMEM containing 5% FBS and antibiotics and incubated for 24 h at 37°C in a 5% CO2 incubator. After incubation, the medium was then removed and 50 l of complete medium containing 20 g/ml actinomycin D were added to all wells. In each plate, a standard curve (200, 50, 12.5, 5, 1.5, and 0.5 pg/well) of recombinant rat TNF-␣ in complete medium was set up. Test medium (150 l) was added to the remaining wells. The cells were incubated for 18 h and the medium was decanted. The remaining viable cells were stained with 100 l/well of 0.1% crystal violet in 20% ethanol, rinsed with phosphate-buffered saline, and air dried. The dye was solubilized by the addition of 100 l of methanol 5 min before reading the absorbance of each well on an automated microplate reader Elx 800 (Bio-Tek) at 595 nm. To confirm that the cytotoxicity in the L929 assay was due to TNF-␣, guinea pig anti-murine TNF-␣ antiserum was added to selected samples of medium before assay.
Assay for 6-keto-PGF 1␣. The stable metabolite of prostacyclin 6-keto-PGF1␣ was determined in cell culture medium with a commercially available kit according to the manufacturer instructions (Cayman Chemical).
Electrophoretic mobility shift assay. Whole cell extracts were prepared according to the method of Dent and Latchman (7). To extraction buffer stock (20 mM HEPES, pH 7.8; 450 mM NaCl, 0.4 mM EDTA, and 25% glycerol) was added a complete protease inhibitor cocktail tablet (Boehringer Mannheim) and dithiothreitol (DTT) to 0.5 mM just before use. Extraction buffer was added to frozen vascular smooth muscle cells (150 l to 100 mm plates, 50 l to each well of 12-well plates), and the cells were scraped into microfuge tubes. The cells were given two additional freeze/thaw cycles at Ϫ70°C and 37°C and centrifuged at 13,000 g for 10 min in a microfuge. If not assayed immediately, supernatants were stored at Ϫ70°C. Protein concentrations were determined with the Bio-Rad protein assay kit. Variation in protein concentration among the samples in a given experiment was typically Ͻ20% and the samples were assayed without adjusting the protein concentration.
Each electrophoretic mobility shift assay contained 5 l of whole cell extract, 10 fmol of the P-32 end-labeled, double-stranded oligonucleotide 5Ј-AGTTGAGGGGACTT-TCCCAGGC-3Ј (Promega), which contains the NF-B consensus-binding sequence, and 0.25 g of polydeoxyinosinic-deoxycytidylic acid (Boehringer Mannheim) in 10 mM Tris, pH 7.5, 4% glycerol, 1 mM DTT in a total volume of 20 l. Unlabeled competitor oligonucleotides (1 pmole) were added as indicated. After a 15-min incubation at room temperature, the mixtures were loaded onto a 5% polyacrylamide gel. The gels were electrophoresed at 200 V for 1 h, 20 min in 0.5ϫ Tris-borate-EDTA (0.045 M Trisborate and 1 mM EDTA). Gels were dried and autoradiographed. Bands corresponding to NF-B were identified by homologous competition experiments. Bands were quantitated by densitometry.
RNAse protection assay. RNA was prepared from cells grown on 100-mm plates and stored at Ϫ70°C using the RNeasy mini kit (Qiagen) according to manufacturer directions. Briefly, lysis buffer was applied to the frozen cells; the cell lysate was collected with a cell scraper and applied to a Qiashredder spin column (Qiagen) to shear the genomic DNA. The resulting homogenate was mixed with an equal volume of 70% ethanol and applied to an RNeasy spin col-umn. After washing and elution was completed, the RNA was quantitated by absorbance at 260 nm. The RNA was precipitated by the addition of 0.1 volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes of ethanol and stored at Ϫ70°C until use.
The rat cytokine multiprobe set was obtained from PharMingen that consists of DNA templates that can be transcribed to give probes for the following genes: IL-1␣, IL-1␤, TNF-␤, IL-3, IL-4, IL-5, IL-6, IL-10, TNF-␣, IL-2, interferon-␥, L32, and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). Probes were made by transcribing 1 h at 20°C 0.5 g multiprobe DNA with T7 RNA polymerase in a 20-l reaction volume containing components of the MAXIscript in vitro transcription kit (Ambion) and 100 Ci ␣-[
32 P]UTP, 800 Ci/mM (Amersham). DNA was degraded by the addition of 4 units of RNase-free DNase and incubation for 15 min at 37°C. Yeast tRNA (2 g), 0.3 volumes of 7.5 M ammonium acetate, and 2.5 volumes of ethanol were added to precipitate the RNA probes. After 30 min at Ϫ70°C, the mixture was centrifuged for 15 min at 13,000 g in a microfuge. The pellet was washed with 90% ethanol, air dried, and dissolved in hybridization buffer (80% deionized formamide/100 mM sodium citrate pH 6.4/300 mM sodium acetate pH 6.4/1 mM EDTA).
Aliquots of the RNA stored as an alcoholic precipitate were centrifuged in a microfuge for 15 min at 13,000 g and the supernatants removed. Hybridization buffer and 300,000-500,000 counts per minute of probe were added to each sample in a total volume of 20 l. After the mixtures were heated with vortexing for 5 min at 100°C, the mixtures were hybridized overnight at 50°C. RNase digestion and precipitation of the protected fragments was carried out using the RPAII kit (Ambion) according to manufacturer protocols. Protected fragments were resolved by electrophoresis on a 7 M urea/5% polyacrylamide gel in 0.045 M Tris borate/1-mM EDTA buffer. After being dried, the protected fragments were identified by autoradiography or by visualization in a phosphorimager (Molecular Dynamics). The protected fragments were quantitated by densitometry or by analysis with the ImageQuant software accompanying the phosphorimager.
For those experiments where the rat vascular smooth muscle cells were grown in 12-well plates, RNase protection assays were carried out using the Direct Protect RPA kit (Ambion) according the manufacturer protocols. Briefly, hybridization was carried out in the lysis buffer. In these experiments, the probes were redissolved in lysis buffer after precipitation.
Western blot detection of TNF-␣. After incubation, the cells were washed three times with phosphate-buffered saline and lysed in cell lysis buffer of 50 mM Tris, pH 8.0; 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 100 g/ml phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, and 1% Nonidet P-40. After being boiled for 5 min, protein concentrations were determined with the Bio-Rad DC protein assay kit (Hercules, CA). Samples (200 g/lane) were subjected to SDS-polyacrylaminde gel electrophoresis and transferred to a nitrocellulose membrane in 25 mM Tris, 20% methanol, 192 mM glycine, pH 8.3. After membrane transfer, gels were stained for total protein with Coomassie blue to verify transfer efficiency. The membranes were also reversibly stained with ponceau S to assess the equivalence of sample loading and gel transfer. After being blocked in 5% nonfat milk, the membranes were incubated in 2 g/ml mouse anti-rat-TNF, and followed by horseradish peroxidase-conjugated anti-mouse IgG at 1:3,000 dilution (enhanced chemiluminescence kit, Amersham). The binding of antibody was detected by chemiluminescence and evaluated by densitometry. Prestained protein markers (GIBCO) were used for molecular mass determinations.
Analysis of data. Data were analyzed using Student's ttest, repeated-measures ANOVA, or linear least squares as appropriate.
RESULTS
LPS stimulates the release of TNF-␣ from rat vascular smooth muscle cells in a concentration-dependent manner. In the absence of LPS, TNF-␣ was not detected in the media in which rat vascular muscle cells were growing. Addition of increasing concentrations of LPS resulted in increasing amounts of TNF-␣ production by the cells (Fig. 1A) . The amount of TNF-␣ produced became significant (P Ͻ 0.05) at concentrations of 2.0 g/ml LPS.
We used an LPS concentration of 20 g/ml to determine the time course of TNF-␣ secretion, because the response to LPS was the most robust at that concentration. TNF-␣ was not detected in significant quantities until 120 min after LPS stimulation (Fig. 1B) . A similar time course was seen using 2.0 g/ml LPS (data not shown). Production of TNF-␣ was dependent on new RNA synthesis as treatment of the cells with 20 g/ml actinomycin D before LPS stimulation abolished TNF-␣ production.
LPS stimulation activates NF-B. Activation of transcription of inflammatory cytokine genes is commonly dependent on NF-B (4).
As an initial experiment to determine whether activation of the TNF-␣ gene is directly dependent on NF-B, we examined the time course of NF-B activation by LPS (Fig. 2) . We observed a low basal level of NF-B activity. After addition of 20 g/ml LPS, maximum NF-B activity was reached at 30 min and declined thereafter. Thus, as seen by the comparison of Figs. 1 and 2, there was a substantial lag between the activation of NF-B and the production of TNF-␣ protein.
To determine the time course of the effect of LPS on TNF-␣ mRNA, RNase protection assays were carried out. Total RNA was prepared from vascular smooth muscle cells in culture to which 20 g/ml LPS had been added and allowed to incubate for the indicated time. The probe set used for this experiment contained probes for eleven cytokine genes (IL-1␣, IL-1␤, TNF-␤, IL-3, IL-4, IL-5, IL-6, IL-10, TNF-␣, IL-2, and interferon-␥) and two housekeeping genes (L32 and GAPDH).
Exposure of rat vascular smooth muscle cells to LPS results in increased IL-6, TNF-␣, and IL-␣ mRNAs (Fig. 3) . TNF-␣ message increases with time starting ϳ25 min after LPS addition and continuing to 180 min. A linear least squares analysis of the TNF-␣ signal beginning at 20 min after LPS stimulation indicated an x-intercept of 21 min, consistent with NF-B directly activating transcription of the TNF-␣ gene. Thus onset of the increase of TNF-␣ message correlates with NF-B activation. The amount of IL-6 mRNA also has increased 30 min after LPS stimulation, consistent with this gene also being directly activated by NF-B By contrast, the appearance of IL-1␣ mRNA was delayed. The delay suggests that activation of the IL-1␣ gene in this system is a downstream event in the amplification cascade initiated by LPS. TNF-␣ has been shown to stimulate production of IL-1␣ in vascular smooth muscle cells (26) . Our results are consistent with this observation; the first major increase in IL-1␣ mRNA occurs at 120 min, the time at which secreted TNF-a protein was first detected (Figs. 1B and 3B) .
Aspirin does not inhibit NF-B activation and does not affect the secretion of TNF-␣ protein.
We attempted to test the hypothesis that activation of the TNF-␣ and IL-6 genes is dependent on NF-B by inhibiting the activation NF-B with 20 mM aspirin. This concentration of aspirin has been shown to inhibit activation of NF-B in several systems (11, 13) . However, although aspirin substantially reduced both basal and bradykinin-induced production of 6-keto-PGF 1␣ (Table 1) , aspirin did not affect the activation of NF-B by 20 g/ml LPS. Because 2 g/ml LPS also induced substantial production of TNF-␣, we repeated the experiment using that concentration of LPS (Fig. 4) . Analysis of experiments from cells taken from four different rats showed no significant difference in NF-B activation at either 30 or 180 min, indicating that aspirin did not prevent LPS activation of NF-B.
Analysis of the amount of IL-6 and TNF-␣ mRNA present at 30 and 180 min after LPS addition showed no difference at 180 min. In the presence of 20 mM aspirin, the amount of IL-6 mRNA found 30 min after LPS addition was 39% of the amount of IL-6 mRNA found 30 min after LPS addition in the absence of aspirin (P Ͻ 0.05) (Fig. 5) . Similarly, the amount of TNF-␣ mRNA found 30 min after LPS addition in the presence of 20 mM aspirin was 44% of that found in the absence of aspirin (P Ͻ 0.05, Fig. 6 ). Tracings cover the region from just ϳ225 nt to 125 nt. Note the anomalously low peak at 60 min and the correspondingly low amount of houskeeping genes at that point. D: densitometric analysis of cytokine production after LPS stimulation. Data were combined from 3 experiments using vascular smooth muscle cells from 3 rats. Area of the peaks from densitometric analysis was corrected for loading errors by normalization to a constant value for L32 and plotted by means Ϯ SE. Values are means Ϯ SE for cells cultured from 4 rats. Cells were pretreated with 20 mM aspirin for 30 min and then basal measurements of 6-keto-PGF1␣ (pg/ng cell protein) were made. Additional 6-keto-PGF1␣ measurements were made 15 min after 100 nM bradykinin was added to stimulate prostaglandin release. * P Ͻ 0.05 compared with control.
Western analysis (Fig. 7) showed that aspirin did not affect the translation of TNF-␣ mRNA, because lysates from LPS-stimulated cells showed comparable amounts of TNF-␣ protein whether or not aspirin was present. Dot-blot analysis (not shown) indicated that TNF-␣ protein was secreted into the medium in the presence of aspirin.
DISCUSSION
The results of the above experiments showed that LPS induces the activation of NF-B and the dosedependent production of TNF-␣ by vascular smooth muscle cells in culture. In response to LPS stimulation, increased TNF-␣ mRNA was detected. The initiation of the increase in TNF-␣ mRNA correlated with the activation of NF-B, consistent with the TNF-␣ gene being regulated by NF-B.
Increased IL-6 and IL-1␣ mRNA were also produced in response to LPS; the timing of the onset of the IL-6 increase was also consistent with the gene activation being responsive to NF-B. The increase in IL-1␣ mRNA appeared to be a downstream event. Thus vascular smooth muscle cells were shown capable of producing multiple inflammatory cytokines in response to LPS, indicating the desirability of identifying inflammatory-control agents in this cell type.
The anti-inflammatory effects of aspirin and other salicylates are achieved through multiple mechanisms. In addition to inhibiting prostaglandin-producing cyclooxygenases and preventing NF-B activation, salicylates have also been shown in cardiac fibroblasts to inhibit transcription without inhibiting the activation of NF-B (9). Another mechanism, inhibition of translation, has been shown in the case of IL-1␤ induction of nitric oxide synthase in hepatocytes (22) . In this system also, the activation of NF-B was unaffected by the presence of salicylates.
The question whether salicylates are capable of inhibiting the activation of NF-B in vascular smooth muscle cells remains unresolved. It has been reported that aspirin inhibits inducible nitric oxide synthase expression and TNF-␣ release from cultured bovine vascular smooth muscle cells stimulated by Il-1␤. In addition, aspirin blocks the activation of NF-B in this system (23) . Aspirin also blocks NF-B activation by platelet-derived growth factor in human vascular smooth muscle cells in vitro (16) . By contrast, it has been reported that in rat vascular smooth muscle cells neither salicylate nor aspirin affects inducible nitric oxide synthase mRNA expression or NF-B activation in response to IL-1␤ and TNF-␣ stimulation (12) . Our results are more in agreement with the third report because aspirin did not prevent NF-B activation by LPS and had only transient inhibitory effects on IL-6 and TNF-␣ mRNA levels. The basis for the discrepancies may be a species effect, a result of different aspirin preincubation times, or the result of different signal transduction pathways being activated by different ligands.
Clarification of these points will require the identification of the signal transduction pathways leading to the activation of NF-B. These pathways and the regulation of these pathways will probably vary with ligand and with cell type. In macrophages, salicylates activate phosphorylation of p38 MAPK. The activated p38 MAP kinase inhibits phosphorylation of IB␣, thereby preventing its degradation and the release of activated NF-B (1, 24) . The p38 MAPK-specific inhibitor SB203580, abolishes salicylate inhibition of NF-B activation. However, in rat vascular smooth muscle cells, LPS activates phosphorylation of p38 MAPK (28) . These results suggest that in vascular smooth muscle cells, pathways exist that can override activated p38 MAPK inhibition of NF-B activation. One such potential pathway is known: NF-B inducing kinase activates IB kinase through a signal transduction pathway that is independent of the MAPK cascade (18) .
The failure of aspirin to inhibit the activation of NF-B and subsequent release of inflammatory cytokines in rat vascular smooth muscle cells suggests that cell-type specific anti-inflammatory agents may need to RNase protection assay. Rat smooth muscle cells were incubated with or without 20 mM ASP before addition of 20 g/ml LPS and incubation for the indicated time. Yeast tRNA, lane 7, was hybridized as a negative control. To avoid having the TNF-␣ signal obscured by high background arising from breakdown of the IL-6 band, a probe set was used, in which TNF-␣ was the largest protected band. B: quantitative analysis of TNF-␣ RNA. Amount of each protected band was determined by densitometric analysis using the ImageQuant software accompanying the phosphorimager, corrected for loading errors by normalization to a constant value for L32 and plotted by means Ϯ SE. Data represent determinations on smooth muscle cells derived from 4 rats. *P Ͻ 0.05 vs. LPS 30 min. A repeat of the experiment with smooth muscle cells derived from a second set of 4 rats gave similar results.
